past, it is anticipated that the dermatological composition of this invention. . .

SUMM This invention comprises at least one of the fat-soluble vitamins provitamin D, previtamin D, **vitamin D**, active **vitamin D**, vitamin K or an analog of one of these mixed in a cosmetic or **sunscreen**, and applied topically to the skin in order to prevent exposure of the skin to harmful UV in the neighborhood. . . the form of the solution, ointments, creams, lotions, sprays and treatment conditioners which have conventionally been used in cosmetics and **sunscreens**. Since the use of cosmetics on the skin inhibits the skin's synthesis of **vitamin D** by UV light, it is also possible to supplement **vitamin D** through the skin using the dermatological composition containing **vitamin D** adapted to a cosmetic.

SUMM . . . pili activity, and prevents hair loss. In other words, the use of conventional dermatological compositions interferes with the synthesis of **vitamin D** in the skin. One way of supplying **vitamin D** to the skin is through the topical use of the dermatological composition containing the vitamins D ergocalciferol and **cholecalciferol** of this invention on the skin and hair. The concentration of provitamin D, previtamin D, **vitamin D**, active **vitamin D** or vitamin K in the ophthalmic or dermatological composition for protecting against harmful UV radiation of this invention, since it. . . topical administration, may be about 100 micrograms/ml(g) or less, or at least about 0.01 micrograms/ml(g). Since provitamin D, previtamin D, **vitamin D**, active **vitamin D** and vitamin K are not cytotoxic, they should not affect the ocular tissue or epidermal cells if used in a normal mixture. When the ophthalmic composition or dermatological composition of this invention is used, the provitamin D, previtamin D, **vitamin D**, active **vitamin D** or vitamin K which covers the eyes or skin absorbs a significant amount of harmful UV radiation, and protects ocular and skin tissue from harmful UV radiation. If conventional **vitamin D** and active **vitamin D** preparations are taken orally in large doses, symptoms of **vitamin D** excess occur. Calcium and phosphates rise in the blood, and there is calcification of the kidneys, arteries, smooth muscles, lungs and other soft tissues. The provitamin D, previtamin D, **vitamin D**, active **vitamin D** and vitamin K of the ophthalmic or dermatological compositions of this invention have always been effective in smaller doses, and though some of the **vitamin D** or vitamin K may be absorbed into the blood through the eyes or skin, the side-effects seen with conventional preparations. . .

AN 2000:171025 USPATFULL

PI US 6162801 20001219
WO 9718817 19970529

L3 ANSWER 16 OF 389 USPATFULL

SUMM . . . absorption curve for harmful UV radiation in the neighborhood of 260 nm, one or more of provitamin D, previtamin D, **vitamin D**, active **vitamin D**, vitamin K or an analog of any of these is used as the effective ingredient in the ophthalmic composition or dermatological composition. Effective forms of **vitamin D** include ergocalciferol or **cholecalciferol** as well as active forms of **vitamin D** formed by hydroxylation of the C1 position of the A-ring of the sterol nucleus, side-chain C25 or both C1 and C25. Considering that active **vitamin D** medicines have been used to treat psoriasis in the past, it is anticipated that the dermatological composition of this invention. . .

SUMM This invention comprises at least one of the fat-soluble vitamins provitamin D, previtamin D, **vitamin D**, active **vitamin D**, vitamin K or an analog of one of these mixed in a cosmetic or **sunscreen**, and applied topically to the skin in order to prevent exposure of the skin to harmful UV in the neighborhood. . . the form of the solution, ointments, creams, lotions, sprays and treatment conditioners which have conventionally been used in cosmetics and **sunscreens**. Since the use of cosmetics on the skin inhibits the skin's synthesis of **vitamin D** by UV light, it is also possible to supplement **vitamin D** through the skin using the dermatological composition containing **vitamin D** adapted to a cosmetic.

SUMM . . . pili activity, and prevents hair loss. In other words, the use of conventional dermatological compositions interferes with the synthesis of **vitamin D** in the skin. One way of supplying **vitamin D** to the skin is through the topical use of the dermatological composition containing the vitamins D ergocalciferol and **cholecalciferol** of this invention on the skin and hair. The concentration of provitamin D, previtamin D, **vitamin D**, active **vitamin D** or vitamin K in the ophthalmic or dermatological composition for protecting against harmful UV radiation of this invention, since it. . . topical administration, may be about 100 micrograms/ml(g) or less, or at least about 0.01 micrograms/ml(g). Since provitamin D, previtamin D, **vitamin D**, active **vitamin D** and vitamin K are not cytotoxic, they should not affect the ocular tissue or epidermal cells if used in a normal mixture. When the ophthalmic composition or dermatological composition of this invention is used, the provitamin D, previtamin D, **vitamin D**, active **vitamin D** or vitamin K which covers the eyes or skin absorbs a significant amount of harmful UV radiation, and protects ocular and skin tissue from harmful UV radiation. If conventional **vitamin D** and active **vitamin D** preparations are taken orally in large doses, symptoms of **vitamin D** excess occur. Calcium and phosphates rise in the blood, and there is calcification of the kidneys, arteries, smooth muscles, lungs and other soft tissues. The provitamin D, previtamin D, **vitamin D**, active **vitamin D** and vitamin K of the ophthalmic or dermatological compositions of this invention have always been effective in smaller doses, and though some of the **vitamin D** or vitamin K may be absorbed into the blood through the eyes or skin, the side-effects seen with conventional preparations. . .

AN 2000:171025 USPATFULL

PI US 6162801 20001219
WO 9718817 19970529

L3 ANSWER 16 OF 389 USPATFULL

SUMM . . . absorption curve for harmful UV radiation in the neighborhood of 260 nm, one or more of provitamin D, previtamin D, **vitamin D**, active **vitamin D**, vitamin K or an analog of any of these is used as the effective ingredient in the ophthalmic composition or dermatological composition. Effective forms of **vitamin D** include ergocalciferol or **cholecalciferol** as well as active forms of **vitamin D** formed by hydroxylation of the C1 position of the A-ring of the sterol nucleus, side-chain C25 or both C1 and C25. Considering that active **vitamin D** medicines have been used to treat psoriasis in the past, it is anticipated that the dermatological composition of this invention. . .

SUMM This invention comprises at least one of the fat-soluble vitamins provitamin D, previtamin D, **vitamin D**, active **vitamin D**, vitamin K or an analog of one of these mixed in a cosmetic or **sunscreen**, and applied topically to the skin in order to prevent exposure of the skin to harmful UV in the neighborhood. . . the form of the solution, ointments, creams, lotions, sprays and treatment conditioners which have conventionally been used in cosmetics and **sunscreens**. Since the use of cosmetics on the skin inhibits the skin's synthesis of **vitamin D** by UV light, it is also possible to supplement **vitamin D** through the skin using the dermatological composition containing **vitamin D** adapted to a cosmetic.

SUMM . . . pili activity, and prevents hair loss. In other words, the use of conventional dermatological compositions interferes with the synthesis of **vitamin D** in the skin. One way of supplying **vitamin D** to the skin is through the topical use of the dermatological composition containing the vitamins D ergocalciferol and **cholecalciferol** of this invention on the skin and hair. The concentration of provitamin D, previtamin D, **vitamin D**, active **vitamin D** or vitamin K in the ophthalmic or dermatological composition for protecting against harmful UV radiation of this invention, since it. . . topical administration, may be about 100 micrograms/ml(g) or less, or at least about 0.01 micrograms/ml(g). Since provitamin D, previtamin D, **vitamin D**, active **vitamin D** and vitamin K are not cytotoxic, they should not affect the ocular tissue or epidermal cells if used in a normal mixture. When the ophthalmic composition or dermatological composition of this invention is used, the provitamin D, previtamin D, **vitamin D**, active **vitamin D** or vitamin K which covers the eyes or skin absorbs a significant amount of harmful UV radiation, and protects ocular and skin tissue from harmful UV radiation. If conventional **vitamin D** and active **vitamin D** preparations are taken orally in large doses, symptoms of **vitamin D** excess occur. Calcium and phosphates rise in the blood, and there is calcification of the kidneys, arteries, smooth muscles, lungs and other soft tissues. The provitamin D, previtamin D, **vitamin D**, active **vitamin D** and vitamin K of the ophthalmic or dermatological compositions of this invention have always been effective in smaller doses, and though some of the **vitamin D** or vitamin K may be absorbed into the blood through the eyes or skin, the side-effects seen with conventional preparations. . .

AN 2000:171025 USPATFULL

PI US 6162801 20001219
WO 9718817 19970529

(19)日本国特許庁（ＪＰ）　(12)公開特許公報（Ａ）　(11)特許出願公開番号

特開平8－245362

(43)公開日　平成８年(1996)９月24日

(51)Int.Cl.[6]		識別記号	庁内整理番号	ＦＩ			技術表示箇所
Ａ６１Ｋ	7/48			Ａ６１Ｋ	7/48		
	7/00				7/00	Ｈ	
						Ｗ	
	31/07	ＡＤＡ			31/07	ＡＤＡ	

審査請求　未請求　請求項の数２　ＦＤ　（全　８　頁）

(21)出願番号　特願平7－77181

(22)出願日　平成７年(1995)３月８日

(71)出願人　000195524
生化学工業株式会社
東京都中央区日本橋本町２丁目１番５号

(72)発明者　村山　昭
東京都文京区本駒込２丁目27番18－701号

(72)発明者　田中　重則
東京都小平市小川西町５丁目３番15号

(74)代理人　弁理士　志村　光春

(54)【発明の名称】　紫外線損傷防御用外用剤

(57)【要約】
【目的】紫外線の皮膚到達量を減少させる効果によるのみならず、紫外線による皮膚損傷予防活性及び損傷皮膚回復活性に基づき、皮膚障害の防御効果が飛躍的に向上した紫外線損傷防御用外用剤の提供。
【構成】紫外線防御剤並びに正常皮膚機能維持活性成分及び損傷皮膚回復活性成分としてビタミンＡ、ビタミンＡエステル及びビタミンＡ酸エステルからなる群より選ばれる１種又は２種以上のビタミンＡ類を含んでなることを特徴とする紫外線損傷防御用外用剤。特に、上記ビタミンＡ類の配合比が、外用剤全体に対して、０．０５重量％以上、２．０重量％以下である上記の紫外線損傷防御用外用剤。

useful as **sunscreening** agents. None of the steroids described in these references however is a .DELTA..sup.5,7 steroidal diene or .DELTA..sup.3,5,7 steroidal triene.

SUMM Leigh, U.S. Pat. No. 3,981,996 describes **sunscreening** preparations comprising mixtures of vitamins A and D. It should be noted, of course, that **vitamin D** can be produced from provitamin D (a .DELTA..sup.5,7 steroidal diene) by a sequence of photochemical and thermal isomerization steps.

SUMM . . . suggested the topical application of 1.alpha.,25-dihydroxy-7-dehydrocholesterol as being useful to deliver eq

L3 ANSWER 12 OF 389 CAPLUS COPYRIGHT 2001 ACS

AB Topical prepns. for preventing or reducing the damaging effects of UV-light on skin comprise 1-**hydroxycholecalciferol** and/or 1,25-**dihydroxycholecalciferol** in combination with a **sunscreen** material and preferably also retinol and/or a deriv. thereof. A lotion contained 1,25-**dihydroxycholecalciferol** 0.5, retinol 2, volatile siloxane (DC 345 fluid) 8.2, silicone surfactant (DC 3225C) 12, mineral oil 1.5, petroleum jelly 0.5,. . .

ST **cholecalciferol sunscreen** cosmetic

IT **Sunscreens**
Tocopherols
RL: BIOL (Biological study)
(cosmetics contg. **cholecalciferol** deriv. and, for skin protection from UV-light)

AN 1993:27283 CAPLUS

DN 118:27283

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 512814	A1	19921111	EP 1992-304076	19920506

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, PT, SE

L3 ANSWER 3 OF 389 CAPLUS COPYRIGHT 2001 ACS

TI .**Sunscreens** containing **vitamin D** derivatives and UV absorbers

AB **Sunscreens**, which protect the skin from UV ray and keep good skin conditions, contain **vitamin D** derivs. and UV absorbers. Stearic acid 6.0, sorbitan monostearate 2.0, polyoxyethylene sorbitan monostearate 1.5, 2-(2'-hydroxy-5'-methylphenyl)benztriazole 8.0, propylene glycol 10.0, vitamin D2 0.05, antiseptic agent, antioxidant, perfume, and H2O to 100% were mixed to give a **sunscreen** cream.

ST **sunscreen vitamin D** UV absorber

IT 50-14-6, Vitamin D2 67-97-0, **Vitamin D3** 1173-13-3, **Precholecalciferol** 1406-16-2, **Vitamin D** 51744-66-2, 5,6-trans-Ergocalciferol
RL: BIOL (Biological study)
(**sunscreens** contg. UV absorbers and)

AN 1994:14674 CAPLUS

DN 120:14674

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 05246835	A2	19930924	JP 1992-81599	19920303

L3 ANSWER 18 OF 389 CAPLUS COPYRIGHT 2001 ACS

AB .The title prepns. contain vitamin A, its esters, and/or **vitamin A acid** esters as skin function activators, repair enhancers for damaged skin, and UV **sunscreens**. An aq. soln. contg. retinyl acetate, 2,2'-dihydroxy-4-methoxy-benzophenone, stearic acid monoglyceride, etc., was applied to volunteers to prevent UV-induced skin damage.

AN 1997:303406 CAPLUS
Correction of: 1996:709890

DN 126:282549
Correction of: 125:338745

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 08245362	A2	19960924	JP 1995-77181	19950308

L13 . ANSWER 1 OF 7 DRUGU COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 1984-14515 DRUGU P B
TI Percutaneous Penetration of Methylglyoxal Bis(guanylhydrazone): Effects of Hairless Mouse Epidermis In Vivo.
AU McCullough J L; Weinstein G D; Rosenblum M G; Jenkins J J
LO Irvine, California, Houston, Texas, United States
SO J.Invest.Dermatol. (81, No. 5, 388-92, 1983) 5 Fig. 3 Tab. 16 Ref.
CODEN: JIDEAE ISSN: 0022-202X
AV Department of Dermatology, University of California, Irvine, California College of Medicine, Irvine, California 92717, U.S.A.
LA English
DT Journal
AB **Vehicle N** (VN, Neutrogena) **enhanced** the percutaneous **penetration** of mitoguazone (M, Aldrich) in human skin in vitro and in mouse skin. VN and n-decylmethyl sulfoxide (Cyclo Chem.) also increased epidermal content of M, compared to saline and N-methylpyrrolidone (Nelson) vehicles. Both topical and i.p. M increased S-adenosyl-L -methionine (SAM) decarboxylase. It is suggested that M in VN could be used in the treatment of psoriasis-type disorders.
SH P Pharmacology
B Biochemistry
CC 8 Pharmacokinetics
14 Enzyme Inhibitors
22 Endogenous Compounds
25 Neoplasia
27 Molecular Biology
29 Pharmaceutics
36 Dermatological
CT [01] MITOGUAZONE *DM; MITOGUAZONE *PH; ALDRICH *FT; TETRADECANOYLPHORBOL-ACETATE *RC; MOUSE *FT; HUMAN *FT; SKIN *FT; IN -VITRO *FT; IN-VIVO *FT; DERMATOLOGICAL *FT; TOPICAL *FT; I.P. *FT; CONC. *FT; EC-4.1.1.50 *FT; NUCLEIC-ACID-METAB. *FT; DNA *FT; N -METAB. *FT; PUTRESCINE *FT; SPERMIDINE *FT; SPERMINE *FT; CONC. *FT; AUXILIARY-INGREDIENT *FT; NEUTROGENA *FT; BIOPHARM. *FT; PERCUTANEOUS *FT; ABSORPTION *FT; CYTOSTATICS *FT; LAB.ANIMAL *FT; ADENOSYLMETHIONINE-DECARBOXYLASE *FT; PHARMACEUTICS *FT; MITOGUAZO *RN; DM *FT; PH *FT
FA AB; LA; CT; MPC
FS Literature

=>

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2001 ACS
AN 1982:444209 CAPLUS
DN 97:44209
TI Percutaneous absorption of methotrexate: effect on epidermal DNA synthesis in hairless mice
AU **Ball, Marina A.**; McCullough, Jerry L.; Weinstein, Gerald D.
CS Dep. Dermatol., Univ. California, Irvine, CA, 92717, USA
SO J. Invest. Dermatol. (1982), 79(1), 7-10
CODEN: JIDEAE; ISSN: 0022-202X
DT Journal
LA English
CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 1
GI



I

AB Vehicles were investigated to optimize methotrexate (I) [59-05-2] penetration of skin in vitro, and the effects of a topical I formulation on epidermal DNA synthesis in vivo in the skin of hairless mice were studied. Skin penetration of I was greater with **Vehicle N** (laureth-4, 4% iso-PrOH, propylene glycol, 47.5% EtOH, and H2O) than with H2O and n-decyl Me sulfoxide vehicles. Repeated application of I in **Vehicle N** produced marked epidermal atrophy in treated sites in both normal and hyperproliferative essential fatty acid deficient hairless mouse skin without similar effects at a distant skin site. Local inhibition of epidermal DNA synthesis was also obtained without systemic effects. Thus, I in **Vehicle N** may be useful for the topical therapy of psoriasis.
ST methotrexate skin absorption vehicle; DNA epidermis inhibition methotrexate; psoriasis DNA methotrexate
IT Deoxyribonucleic acid formation
(by epidermis, of hairless mice, inhibition of, by methotrexate topical formulations)
IT Deoxyribonucleic acids
RL: FORM (Formation, nonpreparative)
(formation of, in epidermis in hairless mice, inhibition of, by methotrexate topical formulations)
IT Psoriasis
(methotrexate absorption by skin in relation to treatment of)
IT Skin, metabolism
(epidermis, methotrexate absorption by, DNA formation inhibition in hairless mice in relation to)
IT 59-05-2
RL: BIOL (Biological study)
(absorption of, by skin, epidermal DNA synthesis inhibition in relation to)

L3 ANSWER 2 OF 4 USPATFULL

SUMM . . . exhibited small increases in penetration. Ball et al. (J. Invest. Dermatol. 79:710 (1982)) also observed an increase in penetration using "**Vehicle N**" (alcohol 47.5%, water, laureth 4, isopropyl alcohol 4%, propyleneglycol) from Neutrogena Corporation.

SUMM . . . patients. However, there were no statistical differences in drug treated versus vehicle treated sites one week after therapy was discontinued. **Enhancement** of methotrexate **penetration** into the affected skin in patients with psoriasis resulted in emprovement in the psoriatic plaques with no evidence of systemic. . .

ACCESSION NUMBER: 92:92758 USPATFULL

TITLE: Methotrexate compositions and methods of treatment using same

INVENTOR(S): Loev, Bernard, Scarsdale, NY, United States

PATENT ASSIGNEE(S): Chemex Pharmaceuticals, Inc., Fort Lee, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5166149		19921124
APPLICATION INFO.:	US 1991-713558		19910610 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1989-404424, filed on 8 Sep 1989, now abandoned

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Waddell, Frederick E.

ASSISTANT EXAMINER: Fay, Zohreh A.

LEGAL REPRESENTATIVE: Kenyon & Kenyon

NUMBER OF CLAIMS: 11

EXEMPLARY CLAIM: 1

LINE COUNT: 431

CAS INDEXING IS AVAILABLE FOR THIS PATENT.